Is MNPR or IMNM more profitable?

Monopar Therapeutics' return on equity of -13.08% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Immunome N/A -50.56% -46.93%

Does the media prefer MNPR or IMNM?

In the previous week, Immunome had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Immunome and 3 mentions for Monopar Therapeutics. Immunome's average media sentiment score of 0.51 beat Monopar Therapeutics' score of 0.39 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNPR or CDNA?

In the previous week, CareDx had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for CareDx and 3 mentions for Monopar Therapeutics. CareDx's average media sentiment score of 0.88 beat Monopar Therapeutics' score of 0.39 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAMS or MNPR?

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 3 mentions for Monopar Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.82 beat Monopar Therapeutics' score of 0.39 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MNPR or NRIX?

In the previous week, Monopar Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Monopar Therapeutics and 2 mentions for Nurix Therapeutics. Monopar Therapeutics' average media sentiment score of 0.39 beat Nurix Therapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Monopar Therapeutics (MNPR) Competitors

$96.47 -6.23 (-6.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$96.19 -0.28 (-0.29%)

As of 09/18/2026 07:30 PM Eastern

Compare

MNPR vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

Should you buy Monopar Therapeutics stock or one of its competitors? Monopar Therapeutics's main competitors and comparable companies include Zai Lab (ZLAB), Immunome (IMNM), CareDx (CDNA), NewAmsterdam Pharma (NAMS), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monopar Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Monopar Therapeutics had 3 more articles in the media than Zai Lab. MarketBeat recorded 3 mentions for Monopar Therapeutics and 0 mentions for Zai Lab. Monopar Therapeutics' average media sentiment score of 0.39 beat Zai Lab's score of -0.45 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zai Lab	Neutral
Monopar Therapeutics	Neutral

Zai Lab has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Zai Lab currently has a consensus price target of $37.25, indicating a potential upside of 44.94%. Monopar Therapeutics has a consensus price target of $120.08, indicating a potential upside of 24.48%. Given Zai Lab's higher probable upside, equities analysts clearly believe Zai Lab is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Monopar Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Monopar Therapeutics' return on equity of -13.08% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Monopar Therapeutics	N/A	-13.08%	-12.79%

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Monopar Therapeutics has lower revenue, but higher earnings than Zai Lab. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.35	-$175.54M	-$1.71	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Summary

Monopar Therapeutics beats Zai Lab on 11 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Immunome?

Monopar Therapeutics (NASDAQ:MNPR) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Immunome has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market.

Monopar Therapeutics' return on equity of -13.08% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Immunome	N/A	-50.56%	-46.93%

In the previous week, Immunome had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Immunome and 3 mentions for Monopar Therapeutics. Immunome's average media sentiment score of 0.51 beat Monopar Therapeutics' score of 0.39 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics presently has a consensus target price of $120.08, suggesting a potential upside of 24.48%. Immunome has a consensus target price of $34.64, suggesting a potential upside of 44.50%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Monopar Therapeutics has higher earnings, but lower revenue than Immunome. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A

Summary

Immunome beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Monopar Therapeutics compare to CareDx?

Monopar Therapeutics (NASDAQ:MNPR) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Monopar Therapeutics currently has a consensus price target of $120.08, suggesting a potential upside of 24.48%. CareDx has a consensus price target of $51.20, suggesting a potential downside of 4.89%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Monopar Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, CareDx had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for CareDx and 3 mentions for Monopar Therapeutics. CareDx's average media sentiment score of 0.88 beat Monopar Therapeutics' score of 0.39 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a net margin of 24.23% compared to Monopar Therapeutics' net margin of 0.00%. CareDx's return on equity of 2.87% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
CareDx	24.23%	2.87%	2.17%

1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 2.4% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than CareDx. Monopar Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
CareDx	$379.80M	7.33	-$21.35M	$2.07	26.00

Monopar Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Summary

CareDx beats Monopar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NewAmsterdam Pharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

NewAmsterdam Pharma presently has a consensus price target of $49.73, indicating a potential upside of 121.11%. Monopar Therapeutics has a consensus price target of $120.08, indicating a potential upside of 24.48%. Given NewAmsterdam Pharma's higher probable upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 3 mentions for Monopar Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.82 beat Monopar Therapeutics' score of 0.39 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. Monopar Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	119.49	-$203.82M	-$2.16	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Monopar Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Monopar Therapeutics' return on equity of -13.08% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Summary

NewAmsterdam Pharma beats Monopar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Nurix Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Monopar Therapeutics presently has a consensus price target of $120.08, suggesting a potential upside of 24.48%. Nurix Therapeutics has a consensus price target of $34.21, suggesting a potential upside of 34.49%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Monopar Therapeutics had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Monopar Therapeutics and 2 mentions for Nurix Therapeutics. Monopar Therapeutics' average media sentiment score of 0.39 beat Nurix Therapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monopar Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Monopar Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Nurix Therapeutics	$83.98M	31.44	-$264.46M	-$3.45	N/A

Monopar Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Monopar Therapeutics' return on equity of -13.08% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Summary

Monopar Therapeutics beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$689.34M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-44.46	14.08	273.81	25.39
Price / Sales	N/A	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.68	15.45	10.45	6.33
Net Income	-$13.72M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-12.51%	-1.22%	0.88%	1.17%
1 Month Performance	-22.10%	-4.44%	-1.59%	-2.59%
1 Year Performance	52.43%	37.78%	18.08%	5.97%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	2.5175 of 5 stars	$96.47 -6.1%	$120.08 +24.5%	+45.6%	$689.34M	N/A	N/A	22	High Trading Volume
ZLAB Zai Lab	2.1323 of 5 stars	$24.80 +0.9%	$37.25 +50.2%	-22.1%	$2.80B	$460.16M	N/A	1,784
IMNM Immunome	3.0609 of 5 stars	$23.95 -2.4%	$34.64 +44.6%	+143.4%	$2.79B	$6.94M	N/A	177	Insider Trade
CDNA CareDx	2.6104 of 5 stars	$52.64 +0.5%	$51.20 -2.7%	+264.5%	$2.71B	$379.80M	25.43	765
NAMS NewAmsterdam Pharma	3.5613 of 5 stars	$21.16 -5.4%	$49.73 +135.0%	-15.9%	$2.67B	$22.50M	N/A	100	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

How does Monopar Therapeutics compare to Zai Lab?

Summary

How does Monopar Therapeutics compare to Immunome?

Summary

How does Monopar Therapeutics compare to CareDx?

Summary

How does Monopar Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

How does Monopar Therapeutics compare to Zai Lab?

Does the media prefer ZLAB or MNPR?

Which has more volatility & risk, ZLAB or MNPR?

Do analysts rate ZLAB or MNPR?

Is ZLAB or MNPR more profitable?

Do insiders & institutionals believe in ZLAB or MNPR?

Which has higher valuation & earnings, ZLAB or MNPR?

Summary

How does Monopar Therapeutics compare to Immunome?

Do insiders and institutionals hold more shares of MNPR or IMNM?

Which has more volatility and risk, MNPR or IMNM?

Is MNPR or IMNM more profitable?

Does the media prefer MNPR or IMNM?

Do analysts rate MNPR or IMNM?

Which has stronger valuation & earnings, MNPR or IMNM?

Summary

How does Monopar Therapeutics compare to CareDx?

Do analysts rate MNPR or CDNA?

Does the media favor MNPR or CDNA?

Is MNPR or CDNA more profitable?

Do insiders & institutionals believe in MNPR or CDNA?

Which has stronger valuation and earnings, MNPR or CDNA?

Which has more risk and volatility, MNPR or CDNA?

Summary

How does Monopar Therapeutics compare to NewAmsterdam Pharma?

Do insiders & institutionals have more ownership in NAMS or MNPR?

Which has more risk and volatility, NAMS or MNPR?

Do analysts rate NAMS or MNPR?

Does the media favor NAMS or MNPR?

Which has preferable earnings & valuation, NAMS or MNPR?

Is NAMS or MNPR more profitable?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Do analysts recommend MNPR or NRIX?

Does the media prefer MNPR or NRIX?

Do insiders and institutionals hold more shares of MNPR or NRIX?

Which has more risk & volatility, MNPR or NRIX?

Which has preferable valuation and earnings, MNPR or NRIX?

Is MNPR or NRIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools